North Star Asset Management Inc. Has $3.62 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

North Star Asset Management Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 5.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 125,589 shares of the biopharmaceutical company’s stock after selling 7,327 shares during the period. North Star Asset Management Inc.’s holdings in Pfizer were worth $3,616,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Capital Investment Advisory Services LLC lifted its position in shares of Pfizer by 12.5% during the fourth quarter. Capital Investment Advisory Services LLC now owns 98,200 shares of the biopharmaceutical company’s stock worth $2,827,000 after purchasing an additional 10,931 shares in the last quarter. OLD National Bancorp IN raised its holdings in Pfizer by 12.0% during the 4th quarter. OLD National Bancorp IN now owns 225,102 shares of the biopharmaceutical company’s stock worth $6,481,000 after purchasing an additional 24,165 shares during the last quarter. Brendel Financial Advisors LLC bought a new position in shares of Pfizer in the 4th quarter valued at about $2,854,000. Commerzbank Aktiengesellschaft FI raised its position in shares of Pfizer by 5.0% during the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 241,832 shares of the biopharmaceutical company’s stock valued at $6,962,000 after acquiring an additional 11,497 shares during the last quarter. Finally, PSI Advisors LLC boosted its holdings in Pfizer by 19.1% during the fourth quarter. PSI Advisors LLC now owns 29,508 shares of the biopharmaceutical company’s stock worth $850,000 after buying an additional 4,729 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE traded up $0.31 during mid-day trading on Monday, reaching $26.31. 9,139,223 shares of the stock traded hands, compared to its average volume of 41,983,879. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 1 year low of $25.23 and a 1 year high of $40.37. The company has a market cap of $148.98 billion, a price-to-earnings ratio of 73.03, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The firm has a fifty day moving average price of $27.11 and a 200 day moving average price of $28.62.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same quarter in the previous year, the firm earned $1.14 earnings per share. Pfizer’s revenue was down 41.3% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Wall Street Analyst Weigh In

PFE has been the subject of several recent research reports. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Finally, Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.